<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04405583</url>
  </required_header>
  <id_info>
    <org_study_id>Occ2020_01</org_study_id>
    <nct_id>NCT04405583</nct_id>
  </id_info>
  <brief_title>The AFteR Registry - Follow-up Study to Monitor the Efficacy and Safety of the Occlutech AFR in Heart Failure Patients</brief_title>
  <official_title>A Multicentre, International, Follow-up Study to Monitor the Efficacy and Safety of the Occlutech Atrial Flow Regulator in Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Occlutech International AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Occlutech International AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to monitor the safety and effectiveness of the Occlutech AFR device in
      patients with heart failure for 3 years following AFR device implantation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Safety in the 1 year following implantation</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of patients with at least one SADE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Placement</measure>
    <time_frame>3 years</time_frame>
    <description>Device in situ in the 3 years following implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left-Right shunt through AFR device</measure>
    <time_frame>3 years</time_frame>
    <description>Evidence of left to right shunt through the AFR device in the 3 years following implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA status</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>Change in quality of life as assessed by KCCQ</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Occlutech Atrial Flow Regulator</intervention_name>
    <description>The Occlutech Atrial Flow Regulator is an interatrial shunt device for transcatheter delivery.</description>
    <other_name>Occlutech AFR</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll 100 Patients with Heart Failure over 18 years of age, for whom AFR
        Implantation is indicated and planned.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients for whom Occlutech AFR Implantation is indicated and planned

          -  Age 18 years or older

          -  Written informed consent is available

        Exclusion Criteria:

          -  Any condition that, in the opinion of the investigator might interfere with the
             implantation of affect the patients well-being

          -  Sepsis (local or generalized) or acute infections

          -  Allergy to anti-platelet, anti-coagulant or ani-thrombotic therapy

          -  Allergy to nickel and/or Titanium and or nickel-titanium-based matierials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Svenja Meierarend</last_name>
    <phone>+49 151 141 520 82</phone>
    <email>svenja.meierarend@occlutech.com</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 25, 2020</study_first_submitted>
  <study_first_submitted_qc>May 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>May 25, 2020</last_update_submitted>
  <last_update_submitted_qc>May 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

